Obstructive sleep apnea is a condition that disrupts rest, leading to symptoms such as daytime fatigue, brain fog and ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.

Heart disease is a leading cause of death worldwide, with men particularly susceptible to its often life-threatening ...

A loved one waking you with loud snoring, followed by gasping and choking sounds, might signal more than minor sleep ...

Popular Eli Lilly weight-loss drug Zepbound can be covered by Medicare plans to treat sleep apnea after it received Food and ...

Sleep apnea affects millions globally, often lurking undetected until it begins impacting overall health. While high blood ...

Mineralys Therapeutics, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational ...

There are many consequences of untreated OSA, and all of these are more likely with more-severe obstruction. Because people with OSA don't sleep well, they are at a higher risk for motor vehicle ...

The U.S. FDA has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea.

Estimated 54 million people suffer from obstructive sleep apnea in the U.S. including 30-50% of adults with hypertension, both conditions ...

People whose jobs are highly sedentary – an estimated 80% of the modern workforce – experience a much higher risk of insomnia symptoms, according to a new study led by University of South Florida ...